Neuropsychiatric Disorders
Cannabis-Based Medicinal Products in the Management of Emotionally Unstable Personality Disorder (EUPD): A Narrative Review and Case Series
Waseem Sultan, Anup Mathew, Matthew R. D. Brown, Juan F. Gálvez-Flórez and Guillermo Moreno-Sanz (October 2022)
To our knowledge, this case series represents the first medical evidence of the use of CBMPs (cannabis-based medicinal products) for the clinical management of patients with a diagnosis of EUPD, who are met with limited pharmacological options typically based on the off-label use of psychiatric medications. Cannabinoids may represent a novel, efficacious, and safe treatment alternative for EUPD patients. The neuro- and immune-modulatory effects of THC and CBD seem theoretically well-aligned with cellular and molecular deficits that are currently being investigated as key features underlying the pathogenesis of EUPD. Although preliminary, our results suggest that, when deployed in a rigorously controlled clinical environment, CBMPs can provide substantial improvement in symptoms associated with EUPD thus warranting the need for further research on this therapeutical strategy.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Medical Cannabis For Gilles De Le Tourette Syndrome: An Open Label Prospective Study
Saar Anis, Corinne Zalomek, Amos D. Korczyn, Alina Rosenberg, Nir Giladi and Tanya Gurevich (February 2022)
Assessing the effectiveness and tolerability of medical cannabis (MC) treatment on Gilles de la Tourette syndrome (GTS) patients. We report on an open-label, prospective study on the effect of MC on adult GTS patients. MC mode of use was decided by the treating neurologist and the patient. Δ9-Tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) content within MC product and monthly dose were titrated during the study.
Our results are in line with a number of other studies suggesting that MC is effective and well tolerated in adults with GTS. From our data, it is suggested that MC might be a treatment option for resistant TS patients, and MC has a significant effect on tics, premonitory urges, and patients’ overall quality of life.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis
Sagnik Bhattacharyya, MBBS, MD, PhD; Robin Wilson, MBBS, MRCPsych; Elizabeth Appiah-Kusi, MSc; et al (August 2018)
In this investigation comparing 33 individuals at clinical high risk of psychosis who were part of a double-blind randomized clinical trial and 19 healthy control individuals, a single oral dose of cannabidiol modulated activation in the striatum, medial temporal cortex, and midbrain. In each of these regions, the level of activation following administration of cannabidiol to patients at clinical high risk of psychosis was intermediate between the response in healthy control individuals who did not receive any drug and in patients at clinical high risk receiving placebo.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
The Endocannabinoid System in Mental Disorders: Evidence From Human Brain Studies
Inés Ibarra-Lecue, Fuencisla Pilar-Cuéllar, Carolina Muguruza, Eva Florensa-Zanuy, Álvaro Díaz, Leyre Urigüen, Elena Castro, Angel Pazos, Luis F. Callado (July 2018)
Several studies performed in the last years support the involvement of the endocannabinoid system in the etiopathogenesis of different mental disorders. The present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. We will focus on the findings from human brain studies regarding alterations in endocannabinoid levels, cannabinoid receptors and endocannabinoid metabolizing enzymes in patients suffering mental disorders.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
The Anxiolytic Effects of Cannabidiol in Chronically Stressed Mice are Mediated by the Endocannabinoid System: Role of Neurogenesis and Dendritic Remodeling
Manoela V.Fogaça, Alline C.Campos, Ludmila D.Coelho, Ronald S.Duman, Francisco S.Guimarães (March 2018)
Repeated injections of cannabidiol (CBD), the major non-psychotomimetic compound present in the Cannabis sativa plant, attenuate the anxiogenic effects induced by Chronic Unpredictable Stress (CUS). The specific mechanisms remain to be fully understood but seem to involve adult hippocampalneurogenesis and recruitment of endocannabinoids. Here we investigated for the first time if the behavioral and pro-neurogenic effects of CBD administered concomitant the CUS procedure (14 days) are mediated by CB1, CB2 or 5HT1A receptors, as well as CBD effects on dendritic remodeling and on intracellular/synaptic signaling (fatty acid amide hydrolase – FAAH, Akt, GSK3β and the synaptic proteins Synapsin Ia/b, mGluR1 and PSD95).
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Voluntary Exercise Improves Cognitive Deficits in Female Dominant-Negative DISC1 Transgenic Mouse Model of Neuropsychiatric Disorders
Hadar Segal-Gavish, Ran Barzilay, Ofri Rimoni and Daniel Offen (June 2017)
Voluntary exercise is beneficial in attenuating cognitive deficits observed in a rodent model relevant for neuropsychiatric disorders. The data add a preclinical aspect to the accumulating clinical data supporting the incorporation of physical exercise to patients’ care.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Cannabinoid CB2 Receptor Mechanism of Cannabis sativa L.
Emmanuel S. Onaivi, Hiroki Ishiguro, Qing-Rong Liu (May 2017)
Cannabinoids and many other compounds are constituents in Cannabis sativa L., (cannabaceae) and endocannabinoids (eCBs) are the endogenous marijuana-like substances found in animals and humans. Endocannabinoids, phytocannabinoids and marijuana use activate two cannabinoid receptors (CBRs), CB1Rs and CB2Rs that are encoded in human chromosomes 6 and 1 respectively. New understanding in the science of cannabis botany along with medical and biotechnological advances demonstrate that phytocannabinoids and eCBs acting on CBRs are important regulators of various aspects of physiological, behavioral, immunological and metabolic functions.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Endocannabinoids and Lipid Mediators in Brain Functions
Miriam Melis (2017)
The science of cannabinoids is 50 years old. These past years provided a remarkable and constant number of breakthroughs, showing that the signaling mediated by endocannabinoids and lipid mediators impacts almost every function of the body. Indeed, this represents a special field of research, which allows tackling the complexity of biological functions, and provides potential therapeutic frameworks for a plethora of diseases. The number of exciting discoveries brought up to the scientific community almost on a daily basis highlights the importance of an updated volume on this topic.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Genetic Variation in the Endocannabinoid System and Response to Cognitive Behavior Therapy for Child Anxiety Disorders
Kathryn J. Lester, Jonathan R. I. Coleman, Susanna Roberts, Robert Keers, Gerome Breen, Susan Bögels, Cathy Creswell, Jennifer L. Hudson, Anna McKinnon, Maaike Nauta, Ronald M. Rapee, Silvia Schneider, Wendy K. Silverman, Mikael Thastum, Polly Waite, Gro Janne H. Wergeland,Thalia C. Eley (June 2016)
Extinction learning is an important mechanism in the successful psychological treatment of anxiety. Individual differences in response and relapse following Cognitive Behavior Therapy may in part be explained by variability in the ease with which fears are extinguished or the vulnerability of these fears to re‐emerge. Given the role of the endocannabinoid system in fear extinction, this study investigates whether genetic variation in the endocannabinoid system explains individual differences in response to CBT.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Marc Fakhoury (January 2016)
The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the ECS in schizophrenia and presenting some potential antipsychotic compounds that modulate this system.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses
María-Paz Viveros, Eva-María Marco, Ricardo Llorente, and Meritxell López-Gallardo (June 2007)
Mutant mice lacking CB1 receptors show anxiogenic and depressive-like behaviors as well as an altered hypothalamus pituitary adrenal axis activity, whereas enhancement of endocannabinoid signaling produces anxiolytic and antidepressant-like effects. Genetic and pharmacological approaches also support an involvement of endocannabinoids in extinction of aversive memories. Thus, the endocannabinoid system appears to play a pivotal role in the regulation of emotional states. Endocannabinoids have emerged as mediators of short- and long-term synaptic plasticity in diverse brain structures. Despite the fact that most of the studies on this field have been performed using in vitro models, endocannabinoid-mediated plasticity might be considered as a plausible candidate underlying some of the diverse physiological functions of the endogenous cannabinoid system, including developmental, affective and cognitive processes.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Cannabidiol Attenuates Aggressive Behavior Induced by Social Isolation in Mice: Involvement of 5-HT1A and CB1 Receptors
Alice Hartmann, Sabrina Francesca Lisboa, Andreza Buzolin Sonego, Débora Coutinho, Felipe Villela Gomes and Francisco Silveira Guimaraes (May 2019)
Long-term single housing increases aggressive behavior in mice, a condition named isolation-induced aggression or territorial aggression, which can be attenuated by anxiolytic, antidepressant, and antipsychotic drugs. Preclinical and clinical findings indicate that cannabidiol (CBD), a non-psychotomimetic compound from Cannabis sativa, has anxiolytic, antidepressant, and antipsychotic properties. Few studies, however, have investigated the effects of CBD on aggressive behaviors.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.